A Phase 2 interventional study of IMU-838 and Placebo matching IMU-838 in Multiple Sclerosis, sponsored by Immunic AG. Active, not recruiting at 73 sites in 12 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-04-29.
Sponsored by Immunic AG · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Multiple Sclerosis with a site in Bulgaria — 2 open to participants now, 15 under way, 12 of them phase 3. Multiple Sclerosis · Bulgaria.
Among the 66 studies in Multiple Sclerosis with a site in Bulgaria, this one is the 43rd largest by planned enrollment of the 64 interventional ones that give a count, is one of 4 that started in 2021, is one of 15 in phase 2, reaches primary completion later than 3 of the 14 other live ones, and was the 56th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →2 of the 66 studies in Multiple Sclerosis with a site in Bulgaria are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Bulgaria, United States, Argentina and 33 more countries
Ages 18–65
Hoffmann-La Roche · Sites in Bulgaria, France, Germany and 3 more countries
Ages 18+
A study can be open while its sites in Bulgaria have not opened yet or have stopped. Only those recruiting at a site in Bulgaria →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 16 · Phase 3 48 · Phase 4 1
First in 2006; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 450 is above the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 707 across the 64 interventional studies, 1,152 across the 2 observational. Of the 50 that completed or were terminated, 43 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 66 have an industry lead sponsor. The 10 most frequent:
Immunic AG is the lead sponsor of 7 studies on the registry; none are open to participants now.
Immunic AG has 3 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
2 of the studies in Multiple Sclerosis with a site in Bulgaria that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05134441Phase 3Immunic AGStudy to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | 2026-11 |
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 66 studies in Multiple Sclerosis with a site in Bulgaria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis - CALLIPER
This study will be a multicenter, randomized, double-blind, placebo-controlled study with a blinded Main Treatment Period (MT) and an Open Label Period (OLE) to evaluate the efficacy, safety, and tolerability of IMU838 in adult patients with PMS. The study will consist of the following periods:
Screening Period: Approximately 28 days Main Treatment Period: Up to 120 weeks (approximately 2 years) Open Label Extension Period: Up to approximately 8 years
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
No evidence of relapse in the last 24 months before randomization, AND Patients diagnosed according to 2017 revised McDonald Criteria 1 and the 2013 revised classification of disease courses 2 as either
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IMU-838 as tablet; Administration: Oral - daily
Drug: IMU-838
Matching placebo as tablet; Administration: Oral - daily
Drug: Placebo matching IMU-838
IMU-838 tablets
Also known as: Vidofludimus calcium
Placebo matching IMU-838 tablets
Also known as: Placebo Arm
Efficacy of IMU-838 versus placebo
Annualized rate of percent brain volume change (PBVC) during MT period
Time frame: 120 weeks
Efficacy of IMU-838 versus placebo
Annualized rate of change in brain parenchymal fraction (BPF) during MT Period
Time frame: 120 weeks
Efficacy of IMU-838 versus placebo in terms of disability worsening
Time to 24-week confirmed disability worsening based on expanded disability status scale (EDSS) during MT Period
Time frame: 120 weeks
Safety IMU-838 versus placebo
Adverse events (AEs) and serious AEs (SAEs) during MT Period
Time frame: 120 weeks
Started Sep 2021 (actual). Primary completion is estimated for Jan 2025, 39 months after the start.
Of 43 industry-sponsored phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's planned 39 months is above that.
Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 20 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vidofludimus-calcium
Immunic AG